BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report) traded up 2.9% on Tuesday . The company traded as high as C$5.27 and last traded at C$5.24. Approximately 3,387 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 19,511 shares. The stock had previously closed at C$5.09.
BriaCell Therapeutics Price Performance
The firm has a market capitalization of C$45.59 million, a PE ratio of -6.24 and a beta of 1.98. The business’s 50-day moving average price is C$4.68 and its 200-day moving average price is C$5.67.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to developing novel immunotherapies to fight cancer and improve patients’ lives. Immunotherapies have become the forefront of the fight against cancer because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy, and may also prevent cancer recurrence.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
